Sugi Predict

Sugi Predict / Compounds / Cholesterol

Cholesterol

Cholesterol

SCHEMBL1369757

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.O=CO

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 6/20 0.91
▸ RORC P51449 5/20 0.91
▸ OSBP2 Q969R2 3/20 0.91
▸ USP2 O75604 1/20 0.91
▸ LMNA P02545 1/20 0.91
▸ ABCB1 P08183 1/20 0.91
▸ CYP46A1 Q9Y6A2 1/20 0.91
▸ GRIN1 Q05586 6/20 0.78
▸ GRIN2A Q12879 6/20 0.78
▸ NR1H3 Q13133 7/20 0.77
▸ NPC1L1 Q9UHC9 2/20 0.74
▸ CRYAB P02511 1/20 0.74
▸ HMGCR P04035 1/20 0.74
▸ ITGB3 P05106 1/20 0.74
▸ ITGAV P06756 1/20 0.74
▸ SREBF2 Q12772 1/20 0.74
▸ GRIN2B Q13224 5/20 0.73
▸ EPHA2 P29317 1/20 0.72
▸ DHCR24 Q15392 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL19460298 1.00 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27802336 0.95 OSBP (0.89) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL10481854 0.95 OSBP (0.96) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21539517 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL23365796 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL23761109 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21447271 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21707472 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21650234 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21445079 0.95 OSBP (1.00) OSBPRORCOSBP2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116847888-A Composition for reducing hair whitening, promoting hair growth and/or preventing or reducing hair loss comprising double-stranded miRNA as active ingredient 柏业公司 2023-10-03 — — CN claimed
EP-4229639-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS Global Biopharma, Inc. (CA) 2023-08-23 — — EP claimed
CN-116157521-A Double-stranded oligonucleotides and compositions containing same for the treatment of covd-19 柏业公司 2023-05-23 — — CN claimed
CN-114981433-A CTGF gene-specific double-stranded oligonucleotides and compositions comprising the same for preventing and treating fibrotic diseases and respiratory-related diseases 柏业公司 2022-08-30 — — CN claimed
WO-2022081889-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS GLOBAL BIOPHARMA, INC. (CA) 2022-04-21 — — WO claimed
US-11219692-B2 Porphyrin modified telodendrimers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-01-11 — — US claimed
CN-112159807-A Novel double-stranded oligo-RNA and pharmaceutical composition for preventing or treating fibrosis or respiratory disease comprising the same 柏业公司 2021-01-01 — — CN claimed
US-20200046841-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-13 — — US claimed
US-10406233-B2 Telodendrimers with enhanced drug delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-10 — — US claimed
US-10238750-B2 Porphyrin modified telodendrimers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-03-26 — — US claimed
US-20150045419-A1 REVERSIBLY CROSSLINKED MICELLE SYSTEMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-02-12 — — US claimed
US-20140363371-A1 TELODENDRIMERS WITH ENHANCED DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2014-12-11 — — US claimed
US-8895055-B2 Telodendrimer nanodiscs without apolipoprotein THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-25 — — US claimed
EP-2793953-A1 TELODENDRIMERS WITH ENHANCED DRUG DELIVERY The Regents of The University of California (US) 2014-10-29 — — EP claimed
WO-2014093675-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-19 — — WO claimed
US-20140161719-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-12 — — US claimed
EP-2707419-A2 REVERSIBLY CROSSLINKED MICELLE SYSTEMS The Regents of the University of California (US) 2014-03-19 — — EP claimed
WO-2013096388-A1 TELODENDRIMERS WITH ENHANCED DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-27 — — WO claimed
US-20130164369-A1 TELODENDRIMER NANODISCS WITHOUT APOLIPOPROTEIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-27 — — US claimed
WO-2012158622-A2 REVERSIBLY CROSSLINKED MICELLE SYSTEMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045419-A1 REVERSIBLY CROSSLINKED MICELLE SYSTEMS CETP, NR1H4, ABCB4 OSBP 2179/4885RORC 2822/4885OSBP2 1814/4885
US-10238750-B2 Porphyrin modified telodendrimers CETP, NR1H4, ABCB4 OSBP 961/4885RORC 2367/4885OSBP2 1000/4885
US-20140363371-A1 TELODENDRIMERS WITH ENHANCED DRUG DELIVERY NR1H4, CETP, ABCB11 OSBP 1316/4885RORC 2462/4885OSBP2 1318/4885
US-20140161719-A1 PORPHYRIN MODIFIED TELODENDRIMERS CETP, NR1H4, ABCB4 OSBP 961/4885RORC 2367/4885OSBP2 1000/4885
US-20200046841-A1 PORPHYRIN MODIFIED TELODENDRIMERS CETP, NR1H4, ABCB4 OSBP 961/4885RORC 2367/4885OSBP2 1000/4885
US-10406233-B2 Telodendrimers with enhanced drug delivery NR1H4, CETP, ABCB11 OSBP 1316/4885RORC 2462/4885OSBP2 1318/4885
US-20130164369-A1 TELODENDRIMER NANODISCS WITHOUT APOLIPOPROTEIN CETP, APOB, LDLR OSBP 137/4885RORC 2344/4885OSBP2 312/4885
US-11219692-B2 Porphyrin modified telodendrimers CETP, NR1H4, ABCB4 OSBP 961/4885RORC 2367/4885OSBP2 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.